Amryt to present data from optimal and mpowered phase 3 trials open label extension of mycapssa® (oral octreotide) at endo 2022

Amryt to present data from optimal and mpowered phase 3 trials open label extension of mycapssa® (oral octreotide) at endo 2022
AMYT Ratings Summary
AMYT Quant Ranking